[18F]FAPI-42 PET/CT对肺动脉肿块的诊断价值:与[18F]FDG PET/CT的比较
前瞻性纳入33例临床疑似肺动脉恶性肿瘤患者,行[18F]FAPI-42与[18F]FDG双示踪剂PET/CT。21例恶性肺动脉肿块中FDG均阳性(100%),FAPI阳性20例(95.2%);12例良性肿块两者均阴性。FAPI的靶本比优于FDG,但SUVmax及诊断效能未优于FDG。
要点
- 恶性肺动脉肿块FAPI阳性率95.2%(20/21),FDG阳性率100%(21/21);良性肿块两者均阴性。
- 恶性肿块FAPI与FDG的SUVmax无显著差异(11.36 vs. 9.18,p=0.175)。
- FAPI的靶本比(肝脏及左心室)优于FDG,且4例患者FAPI发现更多转移灶。
核心结论
- FAPI PET/CT诊断肺动脉肿块可行,虽不优于FDG PET/CT,但显示更好的靶本对比度和更多阳性病灶。
研究设计与样本
- 前瞻性研究,纳入33例临床疑似肺动脉恶性肿瘤患者(男18例/女15例,平均年龄53.1±15.4岁),行[18F]FAPI-42与[18F]FDG双示踪剂PET/CT,并行组织免疫组化验证FAP表达。
关键影像表现/征象
- 恶性肺动脉肿块FDG均阳性(21/21,100%),FAPI阳性20/21(95.2%);良性肿块FDG与FAPI均阴性(12/12)。
- 恶性肿块FAPI与FDG的SUVmax无显著差异(11.36 vs. 9.18,p=0.175)。
- 恶性肿块FAPI的靶本比(肝脏)为13.04,FDG为5.17(p<0.001);靶本比(左心室)中位数FAPI为7.75,FDG为2.75(p=0.007)。
- 免疫组化(n=16)显示FAP表达水平与FAPI PET/CT摄取强相关(rs=0.712,p=0.002)。
临床应用与阅片要点
- FAPI PET/CT在4例患者中发现比FDG PET更多的转移灶,其中2例分期升级、1例治疗决策改变。
- 作者结论认为FAPI PET/CT诊断肺动脉肿块可行,虽不优于FDG PET/CT,但靶本对比度更好、阳性病灶更多,可能有助于改善疾病管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the potential utility of [18F]fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) for evaluating pulmonary artery (PA) masses, and compare it with [18F]fluorodeoxyglucose (FDG) PET/CT.
METHODS: Participants with clinically suspected PA malignancy were prospectively enrolled and underwent dual-tracer PET/CT ([18F]FAPI-42 and [18F]FDG) imaging. Visual analysis and semi-quantitative parameters were compared between the two types of radiotracers. The tissue specimen underwent immunohistochemical staining to verify FAP expression in the tissue.
RESULTS: Thirty-three patients (18 males/15 females; mean age 53.1 ± 15.4 years) were enrolled. All 21 patients with malignant PA masses were FDG-positive (100%), whereas 20 out of 21 patients were FAPI-positive (95.2%). All 12 patients with benign PA masses were both negative in FDG and FAPI PET. The mean maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR) of FAPI and FDG in malignant PA masses were significantly higher than those of benign masses. Although there was no significant difference in SUVmax between FDG and FAPI in malignant PA masses (11.36 vs. 9.18, p = 0.175), the TBR (liver) and TBR (left ventricle) were more favorable for FAPI than for FDG (13.04 vs. 5.17, p < 0.001); (median: 7.75 vs. 2.75, p = 0.007). Immunohistochemical analysis (n = 16) validated that the level of FAP expression corresponded strongly to the uptake of FAPI in PET/CT scans (rs = 0.712, p = 0.002). For clinical management, FAPI PET found more metastatic lesions than FDG PET in 4 patients, with 2 patients upgrading and 1 patient changing treatment decisions.
CONCLUSIONS: FAPI PET/CT is feasible in the diagnosis of PA masses. Although not superior to FDG PET/CT, FAPI PET/CT showed better target-to-background contrast.
CLINICAL RELEVANCE STATEMENT: This study found that FAPI PET/CT is not superior to FDG PET/CT in diagnosing PA masses, but FAPI PET/CT displays better target-to-background contrast and more positive lesions, which may help improve disease management.
KEY POINTS: Pulmonary malignancies lack specificity in clinical manifestations, laboratory tests, and routine imaging examinations. FAPI PET/CT is not diagnostically better than FDG PET/CT but displays better target-to-background contrast and more positive lesions. Dual-tracer PET/CT ([18F]FAPI-42 and [18F]FDG) imaging improves clinical management of pulmonary artery masses.
引用
- Hou P, Zhong K, Guo W, et al. The diagnostic value of [18F]FAPI-42 PET/CT for pulmonary artery masses: comparison with [18F]FDG PET/CT. Eur Radiol. 2024. PMID: 38834788. doi:10.1007/s00330-024-10821-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。